Pfizer Inc. $PFE Shares Sold by Forvis Mazars Wealth Advisors LLC

Forvis Mazars Wealth Advisors LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 6.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,918 shares of the biopharmaceutical company’s stock after selling 3,571 shares during the period. Forvis Mazars Wealth Advisors LLC’s holdings in Pfizer were worth $1,186,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently added to or reduced their stakes in the company. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the 1st quarter valued at about $27,000. North Capital Inc. acquired a new position in Pfizer in the 1st quarter valued at about $28,000. Bayforest Capital Ltd purchased a new stake in shares of Pfizer in the 1st quarter valued at approximately $28,000. Harbor Asset Planning Inc. acquired a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Finally, Horizon Financial Services LLC purchased a new stake in shares of Pfizer during the 1st quarter valued at approximately $35,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.2%

Shares of NYSE:PFE opened at $24.52 on Monday. The firm has a market capitalization of $139.38 billion, a PE ratio of 13.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.55. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $29.36. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm’s 50-day moving average is $24.89 and its two-hundred day moving average is $24.11.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter last year, the firm posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, November 7th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on PFE shares. Morgan Stanley cut their target price on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research note on Friday, October 10th. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Bank of America upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a research report on Wednesday, October 1st. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.